The University of Chicago Header Logo

Richard Koya

InstitutionUniversity of Chicago
DepartmentObstetrics and Gynecology-Gynecologic Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2023 Dec 15; 133(24). PMID: 38099495; PMCID: PMC10721136.
      Citations:    Fields:    
    2. Cornetta K, Kay S, Urio F, Minja IK, Mbugi E, Mgaya J, Mselle T, Nkya S, Alimohamed MZ, Ndaki K, Bonamino M, Koya RC, Shah LD, Mahlangu J, Drago D, Rangarajan S, Jayandharan GR. Implementation of a gene therapy education initiative by the ASGCT and Muhimbili University of Health and Allied Sciences. Mol Ther. 2023 09 06; 31(9):2561-2565. PMID: 37595584; PMCID: PMC10492022.
      Citations:    Fields:    Translation:Humans
    3. Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Correction to: Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2899. PMID: 35666273; PMCID: PMC9588465.
      Citations:    Fields:    
    4. Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA, Prieto K, Chen A, Smalley KSM, Czerniecki B, Forsyth P, Koya RC, Ruffell B, Cubillos-Ruiz JR, Munn DH, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022 10 10; 40(10):1145-1160.e9. PMID: 36150390; PMCID: PMC9561067.
      Citations: 18     Fields:    Translation:AnimalsCells
    5. Samoranos KT, Krisiewicz AL, Karpinecz BC, Glover PA, Gale TV, Chehadeh C, Ashshan S, Koya R, Chung EY, Lim HL. pH Sensitive Erythrocyte-Derived Membrane for Acute Systemic Retention and Increased Infectivity of Coated Oncolytic Vaccinia Virus. Pharmaceutics. 2022 Aug 28; 14(9). PMID: 36145558; PMCID: PMC9504069.
      Citations: 1     
    6. Zangari B, Tsuji T, Matsuzaki J, Mohammadpour H, Eppolito C, Battaglia S, Ito F, Chodon T, Koya R, Robert McGray AJ, Odunsi K. Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898. PMID: 35460379; PMCID: PMC9588092.
      Citations:    Fields:    Translation:HumansCells
    7. Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402. PMID: 35294258; PMCID: PMC9311231.
      Citations: 18     Fields:    Translation:HumansAnimals
    8. Ying L, Yazdani M, Koya R, Zhao R. Engineering tumor stromal mechanics for improved T cell therapy. Biochim Biophys Acta Gen Subj. 2022 04; 1866(4):130095. PMID: 35077823.
      Citations: 2     Fields:    Translation:Humans
    9. Muthuswamy R, McGray AR, Battaglia S, He W, Miliotto A, Eppolito C, Matsuzaki J, Takemasa T, Koya R, Chodon T, Lichty BD, Shrikant P, Odunsi K. CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10). PMID: 34607898; PMCID: PMC8491420.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    10. Xu Y, Koya R, Ask K, Zhao R. Engineered microenvironment for the study of myofibroblast mechanobiology. Wound Repair Regen. 2021 07; 29(4):588-596. PMID: 34118169; PMCID: PMC8254796.
      Citations: 1     Fields:    Translation:Cells
    11. Want MY, Tsuji T, Singh PK, Thorne JL, Matsuzaki J, Karasik E, Gillard B, Cortes Gomez E, Koya RC, Lugade A, Odunsi K, Battaglia S. WHSC1/NSD2 regulates immune infiltration in prostate cancer. J Immunother Cancer. 2021 02; 9(2). PMID: 33589522; PMCID: PMC7887377.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    12. Cheruku RR, Cacaccio J, Durrani FA, Tabaczynski WA, Watson R, Siters K, Missert JR, Tracy EC, Dukh M, Guru K, Koya RC, Kalinski P, Baumann H, Pandey RK. Synthesis, Tumor Specificity, and Photosensitizing Efficacy of Erlotinib-Conjugated Chlorins and Bacteriochlorins: Identification of a Highly Effective Candidate for Photodynamic Therapy of Cancer. J Med Chem. 2021 01 14; 64(1):741-767. PMID: 33400524; PMCID: PMC9125565.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    13. Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K. Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019 06 20; 7(1):156. PMID: 31221207; PMCID: PMC6587259.
      Citations: 46     Fields:    Translation:HumansCells
    14. Want MY, Konstorum A, Huang RY, Jain V, Matsueda S, Tsuji T, Lugade A, Odunsi K, Koya R, Battaglia S. Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer. Oncoimmunology. 2019; 8(6):e1586042. PMID: 31069153; PMCID: PMC6492964.
      Citations: 10     Fields:    
    15. Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB, Matsuzaki J, Koya RC, McLeish KR, Qu J, Ram S, Moysich KB, Abrams SI, Odunsi K, Zsiros E, Segal BH, Blom AM. Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment. JCI Insight. 2019 03 07; 4(5). PMID: 30730851; PMCID: PMC6483507.
      Citations: 70     Fields:    Translation:HumansCells
    16. Matsuzaki J, Tsuji T, Chodon T, Ryan C, Koya RC, Odunsi K. A rare population of tumor antigen-specific CD4+CD8+ double-positive aß T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells. J Immunother Cancer. 2019 01 09; 7(1):7. PMID: 30626427; PMCID: PMC6325755.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    17. Khot A, Matsueda S, Thomas VA, Koya RC, Shah DK. Measurement and Quantitative Characterization of Whole-Body Pharmacokinetics of Exogenously Administered T Cells in Mice. J Pharmacol Exp Ther. 2019 03; 368(3):503-513. PMID: 30622170; PMCID: PMC6382992.
      Citations: 24     Fields:    Translation:AnimalsCells
    18. Matsueda S, Chodon T, Koya RC. Cellular Immunotherapy in the Treatment of Hematopoietic Malignancies. Adv Exp Med Biol. 2019; 1143:217-229. PMID: 31338822.
      Citations: 2     Fields:    Translation:HumansCells
    19. Tsuji T, Yoneda A, Matsuzaki J, Miliotto A, Ryan C, Koya RC, Odunsi K. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res. 2018 05; 6(5):594-604. PMID: 29588318; PMCID: PMC5932240.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    20. Su Y, Wei W, Robert L, Xue M, Tsoi J, Garcia-Diaz A, Homet Moreno B, Kim J, Ng RH, Lee JW, Koya RC, Comin-Anduix B, Graeber TG, Ribas A, Heath JR. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A. 2017 12 26; 114(52):13679-13684. PMID: 29229836; PMCID: PMC5748184.
      Citations: 109     Fields:    Translation:HumansCells
    21. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2016 Jan; 126(1):402-3. PMID: 26595810; PMCID: PMC4701538.
      Citations: 9     Fields:    
    22. Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. 2015 May 05; 15:356. PMID: 25939769; PMCID: PMC4432503.
      Citations: 33     Fields:    Translation:AnimalsCells
    23. Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Ribas A, Comin-Anduix B. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18; 7(279):279ra41. PMID: 25787767; PMCID: PMC4765379.
      Citations: 283     Fields:    Translation:HumansAnimalsCells
    24. Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell. 2015 Feb 09; 27(2):240-56. PMID: 25600339; PMCID: PMC4326539.
      Citations: 173     Fields:    Translation:HumansCells
    25. Chodon T, Koya RC, Odunsi K. Active Immunotherapy of Cancer. Immunol Invest. 2015; 44(8):817-36. PMID: 26575466.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    26. Gschweng EH, McCracken MN, Kaufman ML, Ho M, Hollis RP, Wang X, Saini N, Koya RC, Chodon T, Ribas A, Witte ON, Kohn DB. HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice. Cancer Res. 2014 Sep 15; 74(18):5173-83. PMID: 25038231; PMCID: PMC4167467.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    27. Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, Ribas A. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology. 2014; 3:e29244. PMID: 25083336; PMCID: PMC4108466.
      Citations: 50     Fields:    
    28. Chodon T, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A, Comin-Anduix B. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374; PMCID: PMC4070853.
      Citations: 113     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    29. Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Koya RC, Graeber TG, Robins H, Ribas A, Comin-Anduix B. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 01; 20(9):2424-32. PMID: 24583799; PMCID: PMC4008652.
      Citations: 200     Fields:    Translation:HumansCells
    30. Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68. PMID: 24795358; PMCID: PMC4010948.
      Citations: 12     Fields:    Translation:HumansCells
    31. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. PMID: 24265155; PMCID: PMC3936420.
      Citations: 493     Fields:    Translation:HumansCells
    32. Shi H, Hong A, Kong X, Koya RC, Song C, Moriceau G, Hugo W, Yu CC, Ng C, Chodon T, Scolyer RA, Kefford RF, Ribas A, Long GV, Lo RS. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 2014 Jan; 4(1):69-79. PMID: 24265152; PMCID: PMC3893054.
      Citations: 98     Fields:    Translation:HumansCells
    33. Mok S, Koya RC, Tsui C, Xu J, Wu L, Graeber T, West BL, Bollag G, Ribas A, Robert L. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014 Jan 01; 74(1):153-161. PMID: 24247719; PMCID: PMC3947337.
      Citations: 171     Fields:    Translation:AnimalsCells
    34. Ibarrondo FJ, Yang OO, Chodon T, Avramis E, Lee Y, Sazegar H, Jalil J, Chmielowski B, Koya RC, Schmid I, Gomez-Navarro J, Jamieson BD, Ribas A, Comin-Anduix B. Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829. PMID: 24167550; PMCID: PMC3805549.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    35. Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR. Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29. PMID: 23519018; PMCID: PMC3716460.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    36. Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J, Birkhäuser FD. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. PMID: 23377663; PMCID: PMC6410717.
      Citations: 13     Fields:    Translation:AnimalsCells
    37. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest. 2013 Mar; 123(3):1371-81. PMID: 23454771; PMCID: PMC3582139.
      Citations: 149     Fields:    Translation:HumansAnimalsCells
    38. Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Ramirez-Montagut T, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J. A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med. 2012 Nov 05; 10:218. PMID: 23127127; PMCID: PMC3551774.
      Citations: 1     Fields:    Translation:HumansCells
    39. Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFß) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med. 2012 Jun 19; 10:127. PMID: 22713761; PMCID: PMC3507675.
      Citations: 16     Fields:    Translation:AnimalsCells
    40. Koya RC, Mok S, Otte N, Blacketor KJ, Comin-Anduix B, Tumeh PC, Minasyan A, Graham NA, Graeber TG, Chodon T, Ribas A. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012 Aug 15; 72(16):3928-37. PMID: 22693252; PMCID: PMC3422880.
      Citations: 115     Fields:    Translation:HumansAnimalsCells
    41. von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19; 11:22. PMID: 22515704; PMCID: PMC3444881.
      Citations: 41     Fields:    Translation:HumansCells
    42. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2012 May; 2(5):414-24. PMID: 22588879; PMCID: PMC3594852.
      Citations: 48     Fields:    Translation:HumansCells
    43. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun. 2012 Mar 06; 3:724. PMID: 22395615; PMCID: PMC3530385.
      Citations: 318     Fields:    Translation:HumansCells
    44. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R, Robert L. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15. PMID: 22256804; PMCID: PMC3724537.
      Citations: 402     Fields:    Translation:HumansAnimalsCTClinical Trials
    45. Vatakis DN, Koya RC, Nixon CC, Wei L, Kim SG, Avancena P, Bristol G, Baltimore D, Kohn DB, Ribas A, Radu CG, Galic Z, Zack JA. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):E1408-16. PMID: 22123951; PMCID: PMC3251070.
      Citations: 69     Fields:    Translation:HumansAnimalsCells
    46. Konkankit VV, Kim W, Koya RC, Eskin A, Dam MA, Nelson S, Ribas A, Liau LM, Prins RM. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway. J Transl Med. 2011 Nov 07; 9:192. PMID: 22060015; PMCID: PMC3229551.
      Citations: 26     Fields:    Translation:HumansCells
    47. Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA, Radu CG, Ribas A, Heath JR. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011 Jun; 17(6):738-43. PMID: 21602800; PMCID: PMC3681612.
      Citations: 170     Fields:    Translation:HumansCells
    48. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. PMID: 21558401; PMCID: PMC3117971.
      Citations: 84     Fields:    Translation:HumansCellsCTClinical Trials
    49. Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, Escuin-Ordinas H, Chmielowski B, Koya RC, Ribas A, Comin-Anduix B. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010 Dec 15; 16(24):6040-8. PMID: 21169256; PMCID: PMC3057460.
      Citations: 74     Fields:    Translation:HumansCells
    50. Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res. 2011 Feb 15; 71(4):1406-17. PMID: 21159666; PMCID: PMC4180868.
      Citations: 18     Fields:    Translation:HumansCells
    51. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010 Dec 16; 468(7326):973-7. PMID: 21107323; PMCID: PMC3143360.
      Citations: 1078     Fields:    Translation:HumansCells
    52. Ribas A, Koya RC. Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling. Future Oncol. 2010 Nov; 6(11):1671-3. PMID: 21142653.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    53. Zuckerman JE, Hsueh T, Koya RC, Davis ME, Ribas A. siRNA knockdown of ribonucleotide reductase inhibits melanoma cell line proliferation alone or synergistically with temozolomide. J Invest Dermatol. 2011 Feb; 131(2):453-60. PMID: 20944646.
      Citations: 20     Fields:    Translation:HumansCells
    54. Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, Ribas A, Comin-Anduix B. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct; 33(8):759-68. PMID: 20842061; PMCID: PMC3114626.
      Citations: 17     Fields:    Translation:HumansCells
    55. Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, Escuin-Ordinas H, Balderas R, Chmielowski B, Gomez-Navarro J, Koya RC, Ribas A, Comin-Anduix B. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One. 2010 Sep 15; 5(9):e12711. PMID: 20856802; PMCID: PMC2939876.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    56. Brusko TM, Koya RC, Zhu S, Lee MR, Putnam AL, McClymont SA, Nishimura MI, Han S, Chang LJ, Atkinson MA, Ribas A, Bluestone JA. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One. 2010 Jul 22; 5(7):e11726. PMID: 20668510; PMCID: PMC2908680.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    57. Koya RC, Mok S, Chodon T, Radu CG, Nishimura MI, Witte ON, Ribas A, Comin-Anduix B. Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A. 2010 Aug 10; 107(32):14286-91. PMID: 20624956; PMCID: PMC2922609.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    58. Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B, UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. Clin Immunol. 2010 Sep; 136(3):338-47. PMID: 20547105; PMCID: PMC2917536.
      Citations: 20     Fields:    Translation:HumansCells
    59. Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Koya RC, Mischel PS, Lo RS, Ribas A, Søndergaard JN, Comin-Anduix B. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med. 2010 Apr 20; 8:39. PMID: 20406486; PMCID: PMC2876068.
      Citations: 121     Fields:    Translation:HumansAnimalsCells
    60. Koya RC, Liao YP, Ribas A, McBride WH, Schaue D. Immune rejection in a humanized model of murine prostate cancer. Anticancer Res. 2010 Feb; 30(2):409-14. PMID: 20332447.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    61. Jirmo AC, Koya RC, Sundarasetty BS, Pincha M, Yu GY, Lai M, Bakshi R, Schlaphoff V, Grabowski J, Behrens G, Wedemeyer H, Stripecke R. Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses. Vaccine. 2010 Jan 22; 28(4):922-33. PMID: 19931383.
      Citations: 7     Fields:    Translation:HumansCells
    62. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, Schumacher TN, Ribas A, Heath JR. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc. 2009 Jul 22; 131(28):9695-703. PMID: 19552409; PMCID: PMC2720314.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    63. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009 May 20; 7:35. PMID: 19457253; PMCID: PMC2697137.
      Citations: 76     Fields:    Translation:HumansCellsCTClinical Trials
    64. Begley J, Vo DD, Morris LF, Bruhn KW, Prins RM, Mok S, Koya RC, Garban HJ, Comin-Anduix B, Craft N, Ribas A. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol Immunother. 2009 May; 58(5):699-708. PMID: 18807035.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    65. Chhabra A, Yang L, Wang P, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B, Comin-Anduix B. CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol. 2008 Jul 15; 181(2):1063-70. PMID: 18606658; PMCID: PMC2715965.
      Citations: 20     Fields:    Translation:HumansCells
    66. Kimura T, Koya RC, Anselmi L, Sternini C, Wang HJ, Comin-Anduix B, Prins RM, Faure-Kumar E, Rozengurt N, Cui Y, Kasahara N, Stripecke R. Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression. Mol Ther. 2007 Jul; 15(7):1390-9. PMID: 17505480.
      Citations: 21     Fields:    Translation:AnimalsCellsPHPublic Health
    67. Koya RC, Kimura T, Ribas A, Rozengurt N, Lawson GW, Faure-Kumar E, Wang HJ, Herschman H, Kasahara N, Stripecke R. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther. 2007 May; 15(5):971-80. PMID: 17375074.
      Citations: 13     Fields:    Translation:AnimalsCells
    68. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006 Jan 01; 176(1):157-64. PMID: 16365406.
      Citations: 92     Fields:    Translation:HumansAnimalsCells
    69. Qiao H, Koya RC, Nakagawa K, Tanaka H, Fujita H, Takimoto M, Kuzumaki N. Inhibition of Alzheimer's amyloid-beta peptide-induced reduction of mitochondrial membrane potential and neurotoxicity by gelsolin. Neurobiol Aging. 2005 Jun; 26(6):849-55. PMID: 15718043.
      Citations: 21     Fields:    Translation:AnimalsCells
    70. Koya RC, Weber JS, Kasahara N, Lau R, Villacres MC, Levine AM, Stripecke R. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Hum Gene Ther. 2004 Aug; 15(8):733-48. PMID: 15319031.
      Citations: 14     Fields:    Translation:HumansCells
    71. Koya RC, Kasahara N, Favaro PM, Lau R, Ta HQ, Weber JS, Stripecke R. Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery. J Immunother. 2003 Sep-Oct; 26(5):451-60. PMID: 12973034.
      Citations: 19     Fields:    Translation:HumansCells
    72. Stripecke R, Koya RC, Ta HQ, Kasahara N, Levine AM. The use of lentiviral vectors in gene therapy of leukemia: combinatorial gene delivery of immunomodulators into leukemia cells by state-of-the-art vectors. Blood Cells Mol Dis. 2003 Jul-Aug; 31(1):28-37. PMID: 12850480.
      Citations: 12     Fields:    Translation:HumansCells
    73. Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R, Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia. 2002 Sep; 16(9):1645-54. PMID: 12200676.
      Citations: 10     Fields:    Translation:HumansCells
    74. Takimoto M, Wei G, Dosaka-Akita H, Mao P, Kondo S, Sakuragi N, Chiba I, Miura T, Itoh N, Sasao T, Koya RC, Tsukamoto T, Fujimoto S, Katoh H, Kuzumaki N. Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. Br J Cancer. 2002 Jun 05; 86(11):1757-62. PMID: 12087463; PMCID: PMC2375411.
      Citations: 12     Fields:    Translation:HumansCells
    75. Fujita H, Okada F, Hamada J, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N, Fujita H, Okada F, Hamada J, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer. 2001 Sep; 93(6):773-80. PMID: 11519036.
      Citations: 22     Fields:    Translation:Animals
    76. Kusano H, Shimizu S, Koya RC, Fujita H, Kamada S, Kuzumaki N, Tsujimoto Y. Human gelsolin prevents apoptosis by inhibiting apoptotic mitochondrial changes via closing VDAC. Oncogene. 2000 Oct 05; 19(42):4807-14. PMID: 11039896.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    77. Koya RC, Fujita H, Shimizu S, Ohtsu M, Takimoto M, Tsujimoto Y, Kuzumaki N. Gelsolin inhibits apoptosis by blocking mitochondrial membrane potential loss and cytochrome c release. J Biol Chem. 2000 May 19; 275(20):15343-9. PMID: 10809769.
      Citations: 59     Fields:    Translation:HumansAnimalsCells
    78. Wei G, Takimoto M, Yoshida I, Mao PZ, Koya RC, Miura T, Kuzumaki N. Chromosomal assignment of a novel human gene D40. Nucleic Acids Symp Ser. 1999; (42):71-2. PMID: 10780384.
      Citations: 6     Fields:    Translation:HumansCells
    79. Takimoto M, Wei G, Mao PZ, Koya RC, Miura T, Kuzumaki N. Isolation of cDNAs that cover the entire coding region of a novel human protein D40. Nucleic Acids Symp Ser. 1999; (42):69-70. PMID: 10780383.
      Citations:    Fields:    Translation:HumansCells
    80. Kamada S, Kusano H, Fujita H, Ohtsu M, Koya RC, Kuzumaki N, Tsujimoto Y. A cloning method for caspase substrates that uses the yeast two-hybrid system: cloning of the antiapoptotic gene gelsolin. Proc Natl Acad Sci U S A. 1998 Jul 21; 95(15):8532-7. PMID: 9671712; PMCID: PMC21110.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    81. Koya R, Andersen J, Fernandez H, Goodman M, Spector N, Smith R, Hanlon J, Cassileth PA. Analysis of the value of empiric vancomycin administration in febrile neutropenia occurring after autologous peripheral blood stem cell transplants. Bone Marrow Transplant. 1998 May; 21(9):923-6. PMID: 9613785.
      Citations: 3     Fields:    Translation:Humans
    Koya's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (427)
    Co-Authors (3)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors